Objective. To examine how HLA-DRB1 genotypes influence rheumatoid arthritis
(RA) risk; and clinical severity.
Methods. We performed polymerase chain reaction based DRB1 and tumor necros
is factor (TNF) genotyping of 309 Caucasian RA and 283 Caucasian control su
bjects. For risk analyses, we grouped the DRB1 alleles encoding each specif
ic shared epitope: *0401 alone, *0404 with *0102, *0405 with *0408 and *010
1, and *1001 alone. For estimates of RA outcome, we retrospectively obtaine
d data regarding ARA classification criteria, age of disease onset and dise
ase duration, number of slow acting antirheumatic drugs (SAARD) used, and r
heumatoid factor (RF).
Results. Homozygous shared-epitope DRB1 genotypes, compound heterozygous ge
notypes, and simple heterozygous genotypes all conferred elevated relative
risk (RR) for RA (RR 4.3, 11.7, and 3.5, respectively). However, compound h
eterozygous genotypes conferred more risk than either simple heterozygous g
enotype (RR 3.3, p = 0.004) or homozygous genotype (RR 2.8, p = 0.036). The
re was a trend toward more compound heterozygous genotypes in the male RA g
roup than in the female RA group (p < 0.1), and male sex was associated wit
h higher frequency of rheumatoid nodules (56 vs 35% for female RA). RA outc
ome was estimated by number of SAARD used; mean SAARD used was higher in ma
le than in female RA (p < 0.01) and higher in genotypes containing one or 2
shared epitope DRB1 alleles than in those negative for shared epitope DRB1
alleles (p < 0.05). Analyses also suggested that shared epitope DRB1 genot
ype significantly influenced the occurrence of seropositive RA. Seropositiv
e RA fraction was related to either number of shared epitope alleles (0, 1,
or 2) represented in the DRB1 genotype, or, alternatively, to the combinat
ion of sex with shared epitope DRB1 genotype. The presence of one or 2 shar
ed epitope DRB1 alleles influenced the occurrence of high titer seropositiv
e RA as defined by sheep cell agglutination rest (p < 0.01). TNFab microsat
ellite markers and TNF promoter polymorphisms did not influence SAARD numbe
r, seropositive RA, or high titer seropositive RA.
Conclusion. Not all shared epitope DRB1 genotypes conferred the same relati
ve risk, and the male RA group tended to have more compound heterozygous ge
notypes and more severe RA as indicated by rheumatoid nodules and SAARD usa
ge. DRB1 genotypes with one or 2 shared epitope DRB1 alleles influenced the
RA outcome as estimated by numbers of SAARD used and RF.